Table I-9Exposure-based therapies compared with inactive controls (waitlist or usual care)

Domains Pertaining to Strength of EvidenceMagnitude of EffectStrength of Evidence
Number of Studies;
Number of Subjects
Risk of Bias; DesignConsistencyDirectnessPrecisionSummary Effect Size (95% CI)High, Moderate, Low, Insufficient
PTSD Symptom Reduction: CAPS and all PTSD symptom measures
13; 885 (all); 8; 689 (CAPS)Medium; RCTsConsistentDirectPreciseSMD -1.23 (95% CI, -1.50 to -0.97)

SMD(CAPS) -1.12 (95% CI, -1.42 to -0.82))
High
Loss of Diagnosis
6; 409Medium; RCTsConsistentDirectPreciseRD 0.56 (95% CI, 0.35 to 0.78)High
Prevention/reduction of comorbid depression: BDI
10; 715Medium; RCTsConsistentDirectPreciseSMD -0.76 (95% CI, -0.91 to 0.60)High
Prevention/reduction of comorbid anxiety
3; 286N/AConsistentDirectImpreciseAll favored CBT-exposure, p<0.05 for 2 of 3Low
Disability/functional impairment
2; 221aMedium; RCTsInconsistentDirectImpreciseSmall trial (N=31) favored CBT-exposure, p<0.05 but other larger trial found no differences, p=nsInsufficient
a

One trial did not provide sample sizes of each group, so this total includes the PE+CR group which was not included in this analysis.

CI = confidence interval; NA = not applicable; RCT = randomized controlled trial

From: Appendix I, Strength of Evidence

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 207.
Forman-Hoffman V, Middleton JC, Feltner C, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.